Search

Displaying results 1541 - 1550 of 5758 in total
  1. Drug

    Carbamide peroxide

    go.drugbank.com/drugs/DB11129
    ApprovedInvestigational

    Some adverse effects of carbamide peroxide as a dental bleaching agent include dentin sensitivity and/or gingival irritation led by unstable and reactive H+ free radicals and low pH from prolonged use.

  2. Drug

    NC-6300

    go.drugbank.com/drugs/DB17341
    Experimental

    NC-6300, also known as K-912, is a novel [epirubicin] drug-conjugated polymeric micelle.

    Synonyms: NC-6300
  3. Drug

    PRG-A01

    go.drugbank.com/drugs/DB18613
    Investigational

    PRG-A01 is a novel inhibitor of Cu, Zn-superoxide dismutase (SOD1) misfolding and aggregation.

  4. Drug

    Nerinetide

    go.drugbank.com/drugs/DB12595
    Investigational

    Na 1 is under investigation in clinical trial NCT00728182 (Evaluating Neuroprotection in Aneurysm Coiling Therapy).

    Synonyms: Na-1
  5. Drug

    Fosgemcitabine palabenamide

    go.drugbank.com/drugs/DB15057
    Investigational

    NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).

    Synonyms: N-[[P(S)]-2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl]-L-alanine phenylmethyl ester, L-Alanine, N-[[P(S)]-2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl]-, phenylmethyl ester
  6. Drug

    Azelastine

    go.drugbank.com/drugs/DB00972
    ApprovedInvestigational

    [L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.

    Mixtures: N-S-4Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]

    Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitors
  8. Drug

    Nelistotug

    go.drugbank.com/drugs/DB19334
    Investigational

    Cell Carcinoma of the Head and Neck- GALAXIES H&N-202). … Nelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous

  9. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Zylonta also received approval in the EU on December 22, 2022.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    Thyroid, porcine

    go.drugbank.com/drugs/DB09100
    ApprovedInvestigational

    [A190831] Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet.